Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance for the year. The company sells treatments for rare diseases and pediatric endocrinology. During the June quarter, Eton Pharmaceuticals (ETON) generated $37.6 million in sales.
Sales skyrocketed 99% and handily beat expectations for $27.1 million, according to FactSet.
Extract — continue reading at the source.
Related stories
JPMorgan Chase: How To Limit Risk On A Stock That's Doing Well
Luigi Mangione says he will plead guilty over death of UnitedHealth chief executive
Morgan Stanley, JPMorgan Increase Crypto ETF Holdings in Q2
JPMorgan Turns Bullish on Salesforce as the Stock Runs Three Straight Weeks
China's courts rule workers can't be fired just because AI replaced them — and the US has no such protections
SpaceX Closes $60 Billion Cursor Deal: Here's Why This Could Turn Elon Musk's AI Ambitions Into Reality